Phase III, Evaluate Noninferiority Between Levobupivacaine and Bupivacaine in Spinal Anesthesia.

NCT ID: NCT01994967

Last Updated: 2017-07-21

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE3
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-11-30
• Study Completion Date: 2017-01-31

Brief Summary

Clinical trial phase III, noninferiority, controlled, double-blind, randomized. The purpose of this study is to evaluate the noninferiority between Levobupivacaine and Bupivacaine in spinal anesthesia.

Detailed Description

Objectives:

Primary:

• Evaluation of latency to sensory block of T10.
• Evaluation of the duration of sensory block.

Secondary:

• Evaluation of the motor block degree.
• Evaluation of motor block duration.
• Evaluation of cardiovascular safety.
• Block failure.
• Observation of adverse events.

Study Plan:

• Estimated 120 research participants;
• Aged between 18 - 80 in both gender;
• Drug Intervention: 01 day

Evaluations during Trial:

• Classification of anesthetic risk: Class I to VI by the American Society of Anesthesiologists(ASA);
• Identification of the Anesthetic Failure;
• Latency time for sensory block at T10;
• Duration of sensory block and motor block;
• Bromage scale;
• Cardiovascular safety;

Retention of Records:

The investigator shall retain all documentation of the study over a period of at least five years from the end of the study. The Sponsor or its designee will provide a list of all documentation which should be kept by the Investigator.

Monitoring:

All aspects of the study will be carefully monitored by Cristália Pharmaceutical Chemicals Ltda. or designated representative of it (Clinical Research Organization - CRO) for evaluations related to good clinical practice and applicable local regulations.

Case Report Forms. The Monitor will be available if the investigator, or other person of his team, needs information and guidance.

The Monitor of the study should have permanent access to all documentation and it is his obligation to ensure that the Case Report Forms are complete and completed correctly, as well as checking if the data are described according to the source documents, in order to eliminate interferences that may compromise the accuracy of the data generated in the clinical trial.

Audit and Inspections:

Authorized representatives of the Sponsor or designees, regulatory authority or the Ethics Committee of the institution may conduct audits or inspections during or after the study conclusion.

Collecting Data:

The information corresponding to the data of interest from the study will be collected and recorded in Case Report forms provided by Sponsor, and filled from the information contained in the source documents.

Documents are considered sources for study: medical records used by the professional at the time of the visits, diagnostic tests or image.

Informed Consent of Trial:

The Principal Investigator will ensure that the research participant receive verbally and in writing all relevant information about the nature, purpose, the test drug, the possible risks and benefits of the study.

Research participants will be notified that they are free to discontinue the study at any time. That they will have the opportunity to ask questions and to have sufficient time to consider the information received.

Formation of the database:

The database of the study will be assembled with the data from the Case Report Forms. Doubts and discrepancies will generate questions (queries) written to the Principal Investigator.

Conditions

Orthopedic Disorder of Spine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Levobupivacaine

Presentation: injectable solution - ampoule of Levobupivacaine Hydrochloride

Indication: production of subarachnoid block (spinal/ spinal anesthesia).

Group Type: EXPERIMENTAL

Levobupivacaine

Intervention Type: DRUG

Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.

Bupivacaine

Presentation: injectable solution - ampoule of Bupivacaine Hydrochloride

Indication: production of subarachnoid block (spinal/ spinal anesthesia).

Group Type: ACTIVE_COMPARATOR

Bupivacaine

Intervention Type: DRUG

Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.

Interventions

Levobupivacaine

Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.

Intervention Type: DRUG

Bupivacaine

Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.

Intervention Type: DRUG

Other Intervention Names

Levobupivacaine Hydrochloride.; Neocaína ®.; Bupivacaine Hydrochloride.

Eligibility Criteria

Inclusion Criteria

• Patients of both sexes;
• Age between 18 and 80 years;
• Risk anesthetic classified as ASA I or ASA II, according to the American Society of Anesthesiology;
• What have indication for spinal orthopedic surgery in the lower limbs;
• Have agreed to participate and signed the informed consent form.

Exclusion Criteria

• Absolute or relative contraindications to spinal anesthesia;
• Hypersensitivity or intolerance to local anesthetics or to components of the formula;
• Spinal cord injuries, peripheral neuropathy or other neurological condition that lead to sensitivity and/ or motor function disorder;
• Dementia, mental retardation and others important cognitive changes;
• Obesity with a body mass index ( BMI ) ≥ 35 or difficulty in executing the puncture;
• Anatomical column difficulty in the opinion of the investigator;
• Previous spine surgical intervention;
• Polytrauma;
• Tattoo at the puncture site;
• Alcoholism;
• Abuse of illicit substances;
• Antecedents of severe anaphylactic reactions or Steven - Johnson disease;
• Changes in security checks;
• Participation in a clinical study in the 12 months preceding this inclusion;
• Pregnancy and lactation;
• Any other condition that in the opinion of the investigator, may lead to increased risk for the patient.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Newco Trials Pesquisa Científica Ltda

INDUSTRY

Sponsor Role: collaborator

Cristália Produtos Químicos Farmacêuticos Ltda.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Onésimo D. Ribeiro Junior, Medic

Role: PRINCIPAL_INVESTIGATOR

CEMEC

Locations

IMIP - Instituto de Medicina Integral Prof. Fernando Figueira

Recife, Pernambuco, Brazil

Hospital Ernesto Dornelles

Porto Alegre, Rio Grande do Sul, Brazil

Hospital de Base de São José do Rio Preto /SP

São José do Rio Preto, São Paulo, Brazil

Hospital das Clínicas da Faculdade de Medicina da USP / SP

São Paulo, São Paulo, Brazil

CEMEC - Multidisciplinary Center of Clinical Studies

São Paulo, , Brazil

Countries

Brazil

Other Identifiers

CRT074

Identifier Type: -

Identifier Source: org_study_id